Totally agree. I am not expecting much other than a restatement...

First 303 Last

Share
Profile

Follow
Lucretious

5,927 Posts.

1830

05/12/23

10:17

Post #: 71273710
Share

Originally posted by BigDaniel: ↑

I personally don't have any expectations that we will have additional responses, if additional responses are announced than that would be fantastic.

I have the expectation that the final readout for the PTX-100 'phase 1B expanded cohort' will generally be a summary of the already known results over the past years.

I think if we see a final readout without any additional icing, the market should not interpret this negatively.

I think we will see traders rubbishing what they do not understand, nor have the need or want to understand...This is my expectation.

I think we will see smart investors recognizing that the PTX-100 results to date, are already superb and likely to see the drug granted straight to a registrational trial in Q1 or early Q2 of 2024.

So if PTX-100 has at the most, maintained it's excellent safety profile (the purpose of phase 1 trials)... I anticipate that when the bath water settles post final readout that the water will steadily rise as a registrational trial is increasingly likely to be approved in the near term.

The cancers that PTX-100 are targeting are very grave, there is an unmet need...A registrational trial will be a big deal for investors, a big deal for patients and cancer sufferers. It should serve as a huge leap for the company and the market cap should reflect this not withstanding the general macro environment outside of our control.

Expand

Totally agree. I am not expecting much other than a restatement of how well the trial has gone. Anything else is icing. this is an opportunity to remind the medical community of PTX100 and Prescient.

The implications and follow through into Q1 2024 with potential FDA developments or partners is what will drive SP

PTX Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

IRE

Iress runs 'hot' for Wealth Within's stock tips

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

There are more pages in this discussion • 231 more messages in this thread...

First 303 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change -0.002(4.88%)		Mkt cap ! $32.21M

Open	High	Low	Value	Volume
4.1¢	4.2¢	3.9¢	$35.46K	866.3K

Buyers (Bids)

No.	Vol.	Price($)
2	230290	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	79063	1

View Market Depth

No.	Vol.	Price($)
2	230290	0.039
6	551544	0.038
8	387500	0.037
5	708916	0.036
4	303590	0.035

Price($)	Vol.	No.
0.040	79063	1
0.041	42000	1
0.042	37500	1
0.043	654602	5
0.045	217151	3

Last trade - 15.45pm 01/10/2024 (20 minute delay)

PTX (ASX) Chart

Totally agree. I am not expecting much other than a restatement...

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Totally agree. I am not expecting much other than a restatement...

Top Stories

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News